enGene (NASDAQ:ENGN – Get Free Report) and Oncobiologics (NASDAQ:OTLK – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, valuation, analyst recommendations, institutional ownership, profitability and dividends.
Institutional & Insider Ownership
64.2% of enGene shares are owned by institutional investors. Comparatively, 11.2% of Oncobiologics shares are owned by institutional investors. 10.5% of enGene shares are owned by insiders. Comparatively, 1.8% of Oncobiologics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Analyst Ratings
This is a summary of current recommendations and price targets for enGene and Oncobiologics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| enGene | 2 | 8 | 4 | 0 | 2.14 |
| Oncobiologics | 1 | 4 | 2 | 0 | 2.14 |
Profitability
This table compares enGene and Oncobiologics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| enGene | N/A | -56.06% | -45.64% |
| Oncobiologics | N/A | N/A | -291.28% |
Valuation & Earnings
This table compares enGene and Oncobiologics”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| enGene | N/A | N/A | -$117.30 million | ($2.17) | -0.78 |
| Oncobiologics | $333,141.00 | 490.62 | -$62.42 million | ($1.17) | -0.94 |
Oncobiologics has higher revenue and earnings than enGene. Oncobiologics is trading at a lower price-to-earnings ratio than enGene, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
enGene has a beta of -0.28, suggesting that its share price is 128% less volatile than the S&P 500. Comparatively, Oncobiologics has a beta of 0.82, suggesting that its share price is 18% less volatile than the S&P 500.
Summary
enGene beats Oncobiologics on 6 of the 11 factors compared between the two stocks.
About enGene
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.
About Oncobiologics
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
Receive News & Ratings for enGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for enGene and related companies with MarketBeat.com's FREE daily email newsletter.
